NCT01597388 2026-02-24
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
AstraZeneca
Phase 1 Completed
Clinical Trials
6 trialsNCT02208375 2025-12-31
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT02216786 2024-12-02
MANTA
Queen Mary University of London
Phase 2 Completed
NCT02599714 2024-06-06
PASTOR
AstraZeneca
Phase 1 Completed
NCT02583542 2020-02-25
TORCMEK
Queen Mary University of London
Phase 1/2 Unknown